Prostate Cancer最新文献

{"title":"Skeletal Muscle Loss During Treatment With Abiraterone in Patients With Metastatic Prostate Cancer.","authors":"Eva Streckova, Jiri Stejskal, Daniela Kuruczova, Adam Svobodnik, Radka Stepanova, Tomas Buchler","doi":"10.1155/proc/1468262","DOIUrl":"10.1155/proc/1468262","url":null,"abstract":"<p><p><b>Background:</b> Abiraterone acetate is an androgen-receptor pathway inhibitor commonly used for treatment of metastatic prostate cancer. The levels of androgens during treatment with abiraterone acetate with prednisone (AAP) are lower than those achieved by androgen-deprivation therapy only, potentially resulting in a high risk of skeletal muscle loss. <b>Methods:</b> The cohort included 43 patients treated with AAP for metastatic hormone-sensitive prostate cancer or metastatic castration-resistant prostate cancer. To detect and quantify sarcopenia, we utilized standard computer tomography (CT) imaging. Skeletal muscle mass index (SMI) was evaluated by assessing two adjacent axial sections at the level of the L3 vertebra. <b>Results:</b> Sarcopenia at the time of AAP initiation was present in 72.1% of patients. Body mass index (BMI) was inversely associated with the presence of sarcopenia at the time of AAP initiation. There was a statistically significant decrease in SMI over AAP treatment. Age > 75 years and the absence of previous radiotherapy were associated with a higher rate of SMI decrease during AAP therapy. Overall and progression-free survival was not significantly associated with SMI decrease during AAP therapy. <b>Conclusions:</b> SMI decline occurs during AAP treatment for mHSPC and mCRPC, and is more pronounced in patients over 75 years old and those without previous local treatment. There was no statistically significant association between survival outcomes and SMI decline during AAP therapy.</p>","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2025 ","pages":"1468262"},"PeriodicalIF":2.3,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12105893/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144151522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Providing a Prostate Cancer Detection and Prevention Method With Developed Deep Learning Approach.","authors":"Alireza Zarei, Elias Mazrooei Rad, Shahryar Salmani Bajestani, Seyyed Ali Zendehbad","doi":"10.1155/proc/2019841","DOIUrl":"https://doi.org/10.1155/proc/2019841","url":null,"abstract":"<p><p><b>Introduction:</b> Prostate cancer is the second most common cancer among men worldwide. This cancer has become extremely noticeable due to the increase of prostate cancer in Iranian men in recent years due to the lack of marriage and sexual intercourse, as well as the abuse of hormones in sports without any standards. <b>Methods:</b> The histopathology images from a treatment center to diagnose prostate cancer are used with the help of deep learning methods, considering the two characteristics of Tile and Grad-CAM. The approach of this research is to present a prostate cancer diagnosis model to achieve proper performance from histopathology images with the help of a developed deep learning method based on the manifold model. <b>Results:</b> Similarly, in addition to the diagnosis of prostate cancer, a study on the methods of preventing this disease was investigated in literature reviews, and finally, after simulation, prostate cancer presentation factors were determined. <b>Conclusions:</b> The simulation results indicated that the proposed method has a performance advantage over the other state-of-the-art methods, and the accuracy of this method is up to 97.41%.</p>","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2025 ","pages":"2019841"},"PeriodicalIF":2.3,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12081159/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144079935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prostate Cancer Mortality in Iranian Men During 1990-2021: An Age-Period-Cohort and Joinpoint Regression Analysis.","authors":"Fatemeh Jafari, Soheila Khodakarim, Fatemeh Baberi, Abbas Rezaianzadeh","doi":"10.1155/proc/8839773","DOIUrl":"https://doi.org/10.1155/proc/8839773","url":null,"abstract":"<p><p><b>Background:</b> Prostate cancer (PC) ranks as the third cause of cancer-related deaths among Iranian men. The age-period-cohort (APC) model helps identify critical ages, periods, and high-risk birth cohorts to prevent and control PC. Thus, this research aimed to evaluate the effect of APC on PC mortality in Iran from 1990 to 2021. <b>Method:</b> Our data include the number of PC deaths and population, collected by the Global Burden of Disease (GBD) and categorized by 5-year age groups. We computed average annual percentage changes (AAPCs) and relative risks by using joinpoint regression analysis and APC models, respectively. <b>Results:</b> Crude and age-standardized mortality rates for PC were increasing, with AAPC of 2.254% (95% CI: 2.099% and 2.410%; <i>p</i> < 0.001) and 0.257% (95% CI: 0.088% and 0.428%; <i>p</i> < 0.001), respectively. Furthermore, an increase occurred in both age effect from ages 20-24 years (RR = 0.033; 95% CI: 0.023 and 0.046) to over 95 years (RR = 16.183; 95% CI: 14.702 and 17.814) and the period from 1992 (RR = 0.542; 95% CI: 0.516 and 0.570) to 2021 (RR = 1.892; 95% CI: 1.809 and 1.979). While, the cohort effect demonstrated a lower mortality rate in later born than earlier born (Coef = 2.302 for the < 1901 cohort compared to Coef = -2.249 for the 2002-2006 cohort). <b>Conclusion:</b> Our study indicated that the trend of PC deaths in Iran increased during 1990-2021, and the period effect confirms this. Considering fewer deaths in high-income countries due to the widespread implementation of PSA testing, the occurrence of the aging phenomenon in our country, and the upward trend in deaths related to the age effect, sensitizing people and policymakers to conduct PSA screening seems necessary.</p>","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2025 ","pages":"8839773"},"PeriodicalIF":2.3,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11996281/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144009515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preliminary Evidence on Safety and Clinical Efficacy of Luteolin for Patients With Prostate Cancer Under Active Surveillance.","authors":"Taku Naiki, Aya Naiki-Ito, Akihiro Murakami, Hiroyuki Kato, Yosuke Sugiyama, Tatsuya Kawai, Shinji Kato, Toshiki Etani, Takashi Nagai, Nobuhiko Shimizu, Toshiharu Morikawa, Maria Aoki, Masakazu Gonda, Xiaochen Kuang, Yuko Nagayasu, Shuzo Hamamoto, Takahiro Yasui, Satoru Takahashi","doi":"10.1155/proc/8165686","DOIUrl":"10.1155/proc/8165686","url":null,"abstract":"<p><p><b>Background:</b> A need exists for effective treatments for prostate cancer (PCA) due its re-emergence following androgen deprivation therapy, a major clinical problem. In a previous study, we presented evidence on the chemopreventive and chemotherapeutic potential of luteolin, a flavonoid, in PCA including castration-resistant PCA. In this single-arm phase I study, we clinically examined the safety of the oral intake of luteolin in patients under active surveillance (AS). <b>Methods:</b> Between March and September in 2022, five patients with low-intermediate risk PCA and under AS were treated daily with 50 mg of oral luteolin for six months. We investigated the efficacy of oral luteolin in oncological outcomes and any adverse events (AEs) and examined prostate and blood specimens. <b>Results:</b> The median age of patients was 68 years (range: 60-78), and the median initial prostate-specific antigen level was 9.5 ng/mL. All patients were under AS without rapid progression. After treatment with luteolin, AEs were not noted in any patients for six months. All patients underwent a protocol biopsy. Of these, two patients showed a favorable response, one patient had stable disease, and two patients showed disease progression; robot-assisted radical surgery was subsequently performed for the latter. Immunohistochemical analysis revealed decreased expression of androgen receptor and NKX3.1 in noncancerous lesions after luteolin treatment. In addition, quantitative reverse transcription-PCR revealed that serum micro(mi)RNA expression in serum and prostate gland, including miR-29 and miR-30, tended to be upregulated after luteolin treatment compared with during the pretreatment phase. <b>Conclusions:</b> Our small phase I study of men with PCA suggests that daily treatment with 50 mg of an oral supplement of luteolin is safe and effective with regard to oncological outcomes, particularly in patients under AS.</p>","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2025 ","pages":"8165686"},"PeriodicalIF":2.3,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11879532/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143567981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunohistochemical Detection of CD147 Expression in Adenocarcinoma of the Prostate: A Case-Control Study.","authors":"Sara Suliman, Mona Ellaithi","doi":"10.1155/proc/4406057","DOIUrl":"10.1155/proc/4406057","url":null,"abstract":"<p><p>Prostate cancer is the most common noncutaneous malignancy among men worldwide, including in Sudan, where it represents a significant public health challenge. CD147, a transmembrane glycoprotein implicated in tumor progression, invasion, and metastasis, has shown potential as a prognostic biomarker in various cancers. This retrospective case-control study aimed to evaluate CD147 expression in prostate adenocarcinoma among Sudanese men and its association with tumor grade. A total of 80 paraffin-embedded tissue samples, including 40 cases of prostate adenocarcinoma and 40 benign prostatic hyperplasia (BPH) controls, were analyzed using immunohistochemistry. CD147 expression was observed in 22.5% of adenocarcinoma cases compared to 7% of controls; however, the association was not statistically significant (<i>p</i>=0.07). Low-grade tumors were predominant in the cohort, consistent with early-stage diagnoses. The findings revealed no clear link between CD147 expression and tumor grade, diverging from prior studies that associate CD147 with advanced tumor stages. The nonsignificant results may be attributed to the small sample size, emphasizing the need for future research with larger, more diverse cohorts, advanced molecular techniques, and functional studies to better elucidate the role of CD147 in prostate cancer pathogenesis and its potential as a therapeutic target.</p>","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2024 ","pages":"4406057"},"PeriodicalIF":2.3,"publicationDate":"2024-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11682863/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142903166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Number of Prescription Medications and Overall Survival in Metastatic Castrate-Resistant Prostate Cancer.","authors":"Carley R Pickett, Daniel B Eaton, Krishny Karunanandaa, Emily Cybulla, Brendan T Heiden, Su-Hsin Chang, Yan Yan, Melanie P Subramanian, Varun Puri, Martin W Schoen","doi":"10.1155/proc/6863066","DOIUrl":"10.1155/proc/6863066","url":null,"abstract":"<p><p><b>Background:</b> Assessment of comorbid diseases is essential to clinical research and may risk-stratify patients for mortality independent of established methods such as the Charlson Comorbidity Index (CCI). <b>Methods:</b> In a retrospective study of U.S. Veterans, we examined the association between the number of medications, 1-year mortality, and overall survival in Veterans being treated for metastatic castration-resistant prostate cancer (mCRPC) between 2011 and 2017. <b>Results:</b> Among 8855 Veterans, a median of 11 medications and 6 medication classes were filled in the year prior to initial treatment of mCRPC with abiraterone or enzalutamide. The median patient age was 74 years, 25.7% of patients were Black, and the median CCI was 3. Despite being associated with fewer medications, increasing age was associated with an increased CCI. After adjusting for patient, tumor, and treatment factors, both the number of medications and the number of medication classes were associated with increased 1-year mortality with adjusted OR (95% CI) of 1.03 (1.03, 1.04) and 1.08 (1.06, 1.11), respectively. Medications within Anatomic Therapeutic Class (ATC) N (nervous system) and ATC G (genitourinary and sex hormones) were associated with decreased OS, HR 1.18 (1.11, 1.25) and HR 1.15 (1.10, 1.20), respectively. Medications within ATC C (cardiovascular) were associated with increased OS, HR 0.91 (0.86, 0.97). Within a subgroup of patients with comparable age and CCI, the increased number of medications was associated with the increased risk of death. <b>Conclusions:</b> The number and type of medications were independently associated with survival in patients undergoing treatment for mCRPC. With new therapies for treatment of advanced prostate cancer, patients are living longer, which increases the need for better understanding of the impact of comorbid diseases. Simple methods to assess disease burden and prognosticate survival have the potential to guide treatment decisions and improve the quality of life in this patient population.</p>","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2024 ","pages":"6863066"},"PeriodicalIF":2.3,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11669430/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142897143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigating the Relationship of <i>G-137C</i>, <i>C-607A</i>, and <i>A-1447G</i> Polymorphisms in the Promoter of <i>IL-18</i> and <i>CXCL10</i> Inflammatory Genes with Prostate Cancer in an Iranian Population.","authors":"Nahid Ahmadi, Seyyed Amir Yasin Ahmadi, Abdolreza Kheirollahi, Farhad Shahsavar","doi":"10.1155/2024/3997576","DOIUrl":"10.1155/2024/3997576","url":null,"abstract":"<p><strong>Introduction: </strong>Genetic and environmental factors are involved in prostate cancer. The current study was conducted to study the relationship between <i>G-137C</i>, <i>C-607A</i>, and <i>A-1447G</i> polymorphisms in the promoter of <i>IL-18</i> and <i>CXCL10</i> inflammatory genes with prostate cancer.</p><p><strong>Methods: </strong>As a genetic association study with a case-control design, the genomes of people living in Khorasan, Iran, were compared in two groups of cases and controls. The genotype of the <i>A-1447G</i> polymorphism present in the <i>CXCL10</i> gene promoter was investigated by the PCR-RFLP method. PCR-SSP was used to study the genotype of <i>G-137C</i> and <i>C-607A</i> polymorphisms present in the <i>IL-18</i> gene promoter. Odds ratio (OR) and 95% confidence interval (CI) were reported.</p><p><strong>Results: </strong>One mutant allele in <i>CXCL10 A-1447G</i> polymorphism (AG) increased the chance of cancer (OR = 4.902, 95% CI = 2.70-8.87) and two mutant alleles (GG) increased more (OR = 7.174, 95% CI = 2.48-20.68). One mutant allele in <i>IL-18 G-137C</i> polymorphism (CG) increased the chance of cancer (OR = 5.583, 95% CI = 3.04-10.22) and two mutant alleles (CC) increased more (OR = 9.571, 95% CI = 3.10-29.46). One mutant allele in <i>IL-18 C607A</i> polymorphism (CA) increased the chance of cancer (OR = 5.359, 95% CI = 2.95-9.70) and two mutant alleles (AA) increased more (OR = 7.083, 95% CI = 2.61-19.15) (<i>P</i> < 0.001).</p><p><strong>Conclusion: </strong>According to the results, the mutant alleles in polymorphisms <i>CXCL10 A-1447G</i>, <i>IL-18 G-137C</i>, and <i>IL-18 C-607A</i> alleles were associated with an increased chance of prostate cancer in this population.</p>","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2024 ","pages":"3997576"},"PeriodicalIF":2.3,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11446609/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142366361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of Second-Line Treatment for Castration-Resistant Prostate Cancer following the Administration of Upfront Androgen Receptor Signaling Inhibitors.","authors":"Kazuro Kikkawa, Masahiro Tamaki, Kouhei Maruno, Tatsuya Hazama, Toshifumi Takahashi, Yuya Yamada, Masakazu Nakashima, Noriyuki Ito","doi":"10.1155/2024/9303603","DOIUrl":"10.1155/2024/9303603","url":null,"abstract":"<p><p>This study evaluated the effects of docetaxel and androgen receptor signaling inhibitors as second-line treatments in patients with castration-resistant prostate cancer after androgen receptor signaling inhibitors as first-line treatment. This study retrospectively evaluated the clinical outcomes of second-line treatment with docetaxel or androgen receptor signaling inhibitor in patients with castration-resistant prostate cancer who received first-line treatment with androgen receptor signaling inhibitors. Clinical backgrounds and outcomes were compared between docetaxel and androgen receptor signaling inhibitors as second-line treatment. Of 59 patients, 21 (35.6%) and 38 (64.4%) received docetaxel and androgen receptor signaling inhibitors as second-line treatment after first-line treatment with androgen receptor signaling inhibitors, respectively. In the second-line setting, the median progression-free survival was longer with androgen receptor signaling inhibitor than with docetaxel (17 versus 6 months, <i>P</i>=0.014). In the first-line setting, the median progression-free survival was longer with androgen receptor signaling inhibitors than with docetaxel (32 versus 25 months, <i>P</i>=0.014); however, no significant difference was found in the overall survival. Multivariate analysis revealed that there was no significant association between second-line treatment and survival, and first-line treatment with abiraterone was identified as a prognostic factor for progression-free survival. Subgroup analysis showed that the abiraterone-enzalutamide sequence was more effective than the other three sequences for progression-free survival and overall survival. This study suggests that second-line treatment with an androgen receptor signaling inhibitor for castration-resistant prostate cancer after androgen receptor signaling inhibitors as first-line treatment may be more beneficial, particularly with abiraterone as the upfront treatment.</p>","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2024 ","pages":"9303603"},"PeriodicalIF":2.3,"publicationDate":"2024-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11319047/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141971785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Health-Related and Psychosocial Factors Associated with Prostate Cancer Stage at Diagnosis among Males Participating in Alberta’s Tomorrow Project","authors":"Michelle L. Aktary, Brittany Shewchuk, Qinggang Wang, Eric Hyndman, Lorraine Shack, Paula J. Robson, Karen A. Kopciuk","doi":"10.1155/2023/4426167","DOIUrl":"https://doi.org/10.1155/2023/4426167","url":null,"abstract":"Prostate cancer (PCa) stage at diagnosis is an important predictor of cancer prognosis. In Canada, over one-quarter of males are diagnosed with advanced-stage PCa. Studies have identified several factors associated with PCa stage at diagnosis; however, evidence from Canada is limited. This study aimed to examine associations between sociodemographic characteristics, health history, health practices, and psychosocial factors and PCa stage at diagnosis among males participating in Alberta’s Tomorrow Project (ATP), a prospective cohort in Alberta, Canada. The study included males aged 35–69 years who developed PCa until January 2018. Factors associated with PCa stage at diagnosis were examined using partial proportional odds (PPO) ordinal regression models. A total of 410 males were diagnosed with PCa over the study period. A higher number of lifetime prostate-specific antigen tests were associated with earlier-stage PCa (OR 0.91, <math xmlns=\"http://www.w3.org/1998/Math/MathML\" id=\"M1\"> <mi>p</mi> </math> = 0.02, 95% CI 0.83–0.99), while higher abdominal circumference (OR 1.02, <math xmlns=\"http://www.w3.org/1998/Math/MathML\" id=\"M2\"> <mi>p</mi> </math> = 0.05, 95% CI 1.00–1.03), lower social support (OR 2.34, <math xmlns=\"http://www.w3.org/1998/Math/MathML\" id=\"M3\"> <mi>p</mi> </math> < 0.01, 95% CI 1.31–4.17), and having children (OR 2.67, <math xmlns=\"http://www.w3.org/1998/Math/MathML\" id=\"M4\"> <mi>p</mi> </math> < 0.01, 95% CI 1.38–5.16) were associated with later-stage disease. This study identified factors previously found in the literature as well as novel factors associated with PCa stage at diagnosis, which can help inform targets for cancer prevention programs to improve PCa prognosis.","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"78 17","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135093089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cognitive Dysfunction in Patients Treated with Androgen Deprivation Therapy: A Multimodality Functional Imaging Study to Evaluate Neuroinflammation.","authors":"Azeem Saleem,&nbsp;Syed Imran Ali Shah,&nbsp;Stephen A Mangar,&nbsp;Christopher Coello,&nbsp;Matthew B Wall,&nbsp;Gaia Rizzo,&nbsp;Terry Jones,&nbsp;Patricia M Price","doi":"10.1155/2023/6641707","DOIUrl":"10.1155/2023/6641707","url":null,"abstract":"<p><strong>Background: </strong>Androgen deprivation therapy (ADT) for prostate cancer is implicated as a possible cause of cognitive impairment (CI). CI in dementia and Alzheimer's disease is associated with neuroinflammation. In this study, we investigated a potential role of neuroinflammation in ADT-related CI.</p><p><strong>Methods: </strong>Patients with prostate cancer on ADT for ≥3 months were categorized as having ADT-emergent CI or normal cognition (NC) based on self-report at interview. Neuroinflammation was evaluated using positron emission tomography (PET) with the translocator protein (TSPO) radioligand [¹¹C]-PBR28. [¹¹C]-PBR28 uptake in various brain regions was quantified as standardized uptake value (SUVR, normalized to cerebellum) and related to blood oxygen level-dependent functional magnetic resonance imaging (BOLD-fMRI) choice-reaction time task (CRT) activation maps.</p><p><strong>Results: </strong>Eleven patients underwent PET: four with reported CI (rCI), six with reported NC (rNC), and one status unrecorded. PET did not reveal any between-group differences in SUVR regionally or globally. There was no difference between groups on brain activation to the CRT. Regardless of the reported cognitive status, there was strong correlation between PET-TSPO signal and CRT activation in the hippocampus, amygdala, and medial cortex.</p><p><strong>Conclusions: </strong>We found no difference in neuroinflammation measured by PET-TSPO between patients with rCI and rNC. However, we speculate that the strong correlation between TSPO uptake and BOLD-fMRI activation in brain regions involved in memory and known to have high androgen-receptor expression mediating plasticity (hippocampus and amygdala) might reflect inflammatory effects of ADT with compensatory upregulated/increased synaptic functions. Further studies of this imaging readout are warranted to investigate ADT-related CI.</p>","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2023 ","pages":"6641707"},"PeriodicalIF":4.2,"publicationDate":"2023-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10599921/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54230785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}